Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects

Next Previous
Trial Profile

Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Cyclophosphamide; Dexamethasone; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms CHAMPION2
  • Sponsors Onyx Pharmaceuticals

Most Recent Events

  • 01 Mar 2017 Data will be presented at at the 16th International Myeloma Workshop (IMW), according to an Amgen media release.
  • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
  • 17 May 2016 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top